Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set
Nanoform Finland Plc | Company Release | November 12, 2025…
Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License
Nanoform Finland Plc | Inside Information | November 11, 2025…
Invitation to Nanoform’s Q3 2025 Report Presentation
Nanoform Finland Plc | Press Release | October 29, 2025…
Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma
Nanoform Finland Plc | Press Release | October 27, 2025…
Results of Nanoform Collaborative Study to be Presented at the 2025 Partnership Opportunities in Drug Delivery (PODD) Summit
Nanoform Finland Plc | Press Release | October 21, 2025…
Nanoform – Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Nanoform Finland Plc | Company Release | October 16, 2025…
